Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s

Eli Lilly and Company placed a target on the back of recently approved and controversial Alzheimer’s drug Aduhelm (aducanumab) on 26 October, outlining plans during its third quarter earnings call to run a Phase III head-to-head clinical trial testing the company’s donanemab against Biogen, Inc./Eisai Co., Ltd.’s drug to see which antibody does a better job of clearing amyloid from the brain.

The planned head-to-head trial, slated to begin before the end of 2021 and expected to report primary endpoint data during the second half of 2022, was just one of several major research and development updates by the Indianapolis-based firm